Literature DB >> 4333697

Antibodies to respiratory syncytial virus in a normal community in Chandigarh area, northern India.

S C Agarwal, R C Mahajan, J N Bardoloi, N K Ganguly.   

Abstract

A survey for the presence of respiratory syncytial (RS) virus antibodies has been carried out in 346 sera from a healthy community in northern India. The results showed that 19.6% of the sera were positive and had a titre of 16 or more. The higher titres were observed more frequently in the younger age groups. There is, therefore, serological evidence for the occurrence of RS virus infection in India.

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 4333697      PMCID： PMC2427899     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN： 0042-9686            Impact factor:   9.408


  6 in total

1.  Respiratory syncytial virus in Britain.

Authors:  D B PEACOCK; S K CLARKE
Journal:  Lancet       Date:  1961-08-26       Impact factor: 79.321

2.  Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization.

Authors:  R CHANOCK; B ROIZMAN; R MYERS
Journal:  Am J Hyg       Date:  1957-11

3.  Respiratory syncytial virus associated with acute respiratory infections in Trinidadian patients.

Authors:  L Spence; N Barratt
Journal:  Am J Epidemiol       Date:  1968-09       Impact factor: 4.897

4.  Antibodies to respiratory syncytial virus in human sera from different regions of the world.

Authors:  J E Doggett
Journal:  Bull World Health Organ       Date:  1965       Impact factor: 9.408

5.  RESPIRATORY SYNCYTIAL VIRUS STUDIES ON CHILDREN HOSPITALIZED DURING AN OUTBREAK OF RESPIRATORY ILLNESS IN FINLAND.

Authors:  B BERGLUND; L VIHMA; J WICKSTROEM
Journal:  Am J Epidemiol       Date:  1965-05       Impact factor: 4.897

6.  ACUTE RESPIRATORY ILLNESS IN THE PREMATURE NURSERY ASSOCIATED WITH RESPIRATORY SYNCYTIAL VIRUS INFECTIONS.

Authors:  S BERKOVICH
Journal:  Pediatrics       Date:  1964-12       Impact factor: 7.124
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.